ChemoCentryx Announces Two Upcoming Presentations at the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
19
ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress

MOUNTAIN VIEW, Calif., May 23, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI ), today announced two upcoming presentations during the 55th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress, being held in collaboration with the Danish Society of Nephrology (DSN) from May 24-27, 2018 in Copenhagen, Denmark.

Presentation Information:

Abstract Title : Adverse Events with Glucocorticoid Standard of Care Versus Avacopan in ANCA-Associated Vasculitis: Observations from the CLEAR Trial Session Title: Category: I - Glomerulonephritis Poster Presentation Date & Time: : Friday, May 25, 2018, 9:30 a.m. – 10:45 a.m. CEST Authors: David Jayne, Peter Merkel, Antonia Potarca, Thomas Schall, Jan Hillson, Jun Deng, Pirow Bekker Location: Poster Area, Bella Center, Coppenhagen, Denmark

Abstract Title : CCR2 Inhibition Improves Renal Function and Normalizes Glomerular Structure in Focal Segmental Glomerulosclerosis (FSGS) Models Session Title: Free Communication Session: Glomerulonephritis 2 Oral Presentation Date & Time: Saturday, May 26, 2018, 5:35 p.m. CEST Authors: Zhenhua Miao, Linda Ertl, Xiaoping Zang, Bin Zhao, Dale Newland, James Campbell, Jeffrey McMahon, Xiaoli Liu, Ton Dang, Simon Yau, Shichang Miao, Penglie Zhang, Israel Charo, Thomas Schall, Rajinder Singh Location: Hall A3, Bella Center, Coppenhagen, Denmark

About ChemoCentryx

ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx is currently focusing on its late stage drug candidates for patients with rare diseases, avacopan (CCX168) and CCX140.

Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR. Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA-associated Vasculitis). In clinical studies to date, avacopan was shown to be safe and well tolerated and provided effective control of the disease while allowing elimination of high-dose steroids, part of the current standard of care. ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and atypical hemolytic uremic syndrome (aHUS). The U.S. Food and Drug Administration has granted avacopan orphan-drug designation for ANCA-associated Vasculitis, C3G and aHUS. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA-associated Vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G. Avacopan was also granted access to the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) initiative, which supports accelerated assessment of investigational therapies addressing unmet medical need.

The Company's other late stage drug candidate is CCX140, an inhibitor of the chemokine receptor known as CCR2, which is currently being developed for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease.

ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan and CCX140 in markets outside of the U.S. and China.

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya Executive Vice President, Chief Financial and Administrative Officer investor@chemocentryx.com

Media: Stephanie Tomei 408.234.1279 media@chemocentryx.com

Investors: Steve Klass, Burns McClellan 212.213.0006                 sklass@burnsmc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 489

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 114

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 775

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 94

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 106

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 130

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 221

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 292

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
CommBank Yello Builds a Wider Moat Around Customers

Updated Category News Views 23

Nine million customers is not a pilot program; it is a crowded stadium, and CommBank has decided to hand everyone a reason to stay in their seats. Commonwealth Bank's expanded CommBank Yello program now lets eligible customers earn points across home loans, term deposits, cards and insurance, then redeem with well-known brands. That is a serious attempt to make a bank...

Continue Reading

Top 5 Most Recently Viewed Articles

Aitech Honored for Its Breakthrough in Rugged AI Technology

Updated Category News Views 382

Aitech Secures 2025 Artificial Intelligence Excellence Award Aitech, renowned for its rugged embedded systems tailored for military, aerospace, and space applications, has recently been distinguished as a winner in the 2025 Artificial Intelligence Excellence Awards organized by the Business Intelligence Group. This accolade celebrates the innovative strides in AI and...

Continue Reading
National Hydropower Association Emphasizes Hydropower's Importance

Updated Category News Views 129

National Hydropower Association Celebrates Hydropower Day The National Hydropower Association (NHA), the foremost trade association for the water power industry in the U.S., is excited to celebrate National Hydropower Day. This annual event pays tribute to the water power sector and the dedicated American workers who contribute to this essential renewable resource. The...

Continue Reading
Changing Perspectives: German Parents Embrace Cannabis Cultivation

Updated Category News Views 269

Changing Perspectives on Cannabis in Germany In Germany, the landscape of cannabis use has transformed remarkably in the past year. With the legislation on cannabis legalization now in effect, the cultural and social dynamics are evolving. Although there are mixed feelings on the topic, it's evident that younger people, particularly parents, are leaning towards supporting...

Continue Reading
Select Water Solutions Unveils 2025 Q1 Earnings Event Details

Updated Category News Views 257

Select Water Solutions Announces 2025 First Quarter Earnings Select Water Solutions, Inc. (NYSE: WTTR) is gearing up for the announcement of its financial performance for the first quarter of 2025. The company has confirmed the release date of these results, which is set to take place after the market closes on an upcoming Tuesday. This is an exciting time for investors...

Continue Reading
Colabor Group's Strategic Moves Shape Future Financial Outlook

Updated Category News Views 183

Colabor Group's Financial Performance Overview Colabor Group Inc. (TSX: GCL) reveals its financial results for the fourth quarter and fiscal year, providing insights into its ongoing market performance. Fourth Quarter Highlights In the fourth quarter, Colabor Group demonstrated resilience with a sales increase of 3.2%, reaching $202.6 million. Comparatively, sales were at...

Continue Reading